Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft.

Hasskarl J, Zerweck A, Wäsch R, Ihorst G, Bertz H, Finke J.

Bone Marrow Transplant. 2012 Feb;47(2):277-82. doi: 10.1038/bmt.2011.45. Epub 2011 Apr 4.

PMID:
21460873
2.

Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.

Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringdén O, Mattsson J.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1728-37. doi: 10.1016/j.bbmt.2010.06.005. Epub 2010 Jun 10.

3.

Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

de Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I, Tavares R, Lerner D, Byington R, Bouzas L, da Matta J, Andrade C, Carvalho L, Pires V, Barone B, Maciel C, Tabak D.

Bone Marrow Transplant. 2001 Jan;27(1):73-8.

4.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

6.

Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.

Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.

Transplantation. 2009 Dec 15;88(11):1312-8. doi: 10.1097/TP.0b013e3181bbf382.

PMID:
19996931
7.

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.

Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.

Biol Blood Marrow Transplant. 2000;6(3A):309-20.

PMID:
10905768
8.

Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.

Ferrá C, Rodríguez-Luaces M, Gallardo D, Encuentra M, Martín-Henao GA, Peris J, Ancín I, Sarrá J, Berlanga JJ, García J, Grañena A.

Bone Marrow Transplant. 2001 Nov;28(10):963-8.

9.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
10.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

11.

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12.

12.

[Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].

Zhao HX, Sun WJ, Li J, Qiao JX, Huang YJ, Hu HL, Ai HS.

Zhonghua Xue Ye Xue Za Zhi. 2013 Nov;34(11):922-5. doi: 10.3760/cma.j.issn.0253-2727.2013.11.003. Chinese.

PMID:
24294845
14.

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions.

Schaap N, Schattenberg A, Bär B, Preijers F, van de Wiel van Kemenade E, de Witte T.

Leukemia. 2001 Sep;15(9):1339-46.

PMID:
11516094
15.

A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.

Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O, Dörken B, Arnold R.

Bone Marrow Transplant. 2008 May;41(9):805-12. doi: 10.1038/sj.bmt.1705981. Epub 2008 Jan 14.

PMID:
18195682
18.

[Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].

Slesarchuk OA, Babenko EV, Semenova EV, Bondarenko SN, Éstrina MA, Morozova EV, Paina OV, Vavilov VN, Smirnov BI, Zubarovskaia LS, Afanas'ev BV.

Ter Arkh. 2013;85(7):26-33. Russian.

PMID:
24137944
19.

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.

Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ.

Biol Blood Marrow Transplant. 2006 Apr;12(4):414-21.

20.

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.

Bone Marrow Transplant. 2005 Mar;35(6):601-8.

PMID:
15756285

Supplemental Content

Support Center